비교리스트

 카트 문의
시장보고서
상품코드
1546208

세계의 자궁암 치료 및 진단 시장

Uterine Cancer Therapeutics and Diagnostics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 173 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

자궁암 치료 및 진단 세계 시장은 2030년까지 282억 달러에 이를 전망

2023년에 214억 달러로 추정된 자궁암 치료 및 진단 세계 시장은 2030년에는 282억 달러에 이르고, 분석 기간인 2023-2030년간 CAGR 은 4.0%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 자궁내막암 치료 및 진단은 CAGR 4.9%를 나타내고, 분석 기간 종료까지 190억 달러에 이를 것으로 예측됩니다. 자궁 육종 치료 및 진단 부문의 성장률은 분석 기간중 CAGR 2.4%로 추정됩니다.

미국 시장은 추정 57억 달러, 중국은 CAGR7.5%로 성장 예측

미국 자궁암 치료 및 진단시장은 2023년에 57억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 64억 달러 규모에 이를 것으로 예측되어 분석 기간인 2023-2030년간 CAGR 은 7.5%입니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.3%와 4.6%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.7%로 성장할 것으로 예측됩니다.

세계 자궁암 치료 및 진단제 시장 - 주요 동향 및 촉진요인 정리

자궁체암의 발견과 치료가 중요한 이유는 무엇인가?

자궁체암은 여성에게 가장 흔한 암 중 하나이며, 주로 자궁내막암과 자궁육종을 포함합니다. 조기 발견과 효과적인 치료는 생존율과 삶의 질을 향상시키는 데 매우 중요합니다. 전 세계적으로 자궁체부암의 발병률이 증가함에 따라 첨단 치료 및 진단 약품에 대한 수요가 증가하고 있습니다. 경질초음파, 자궁내막 생검, 첨단 영상진단법 등의 기술을 통한 조기 발견은 치료 성적을 크게 향상시킬 수 있습니다. 또한, 수술, 방사선, 화학요법, 호르몬 요법 등 맞춤형 치료법은 특정 암종과 병기를 목표로 진화하고 있으며, 환자의 예후를 개선하고 부작용을 최소화하기 위해 진화하고 있습니다. 분자진단과 바이오마커 검사의 통합은 치료 조정 능력을 더욱 향상시켜 환자가 종양의 유전적 구성에 따라 가장 효과적인 치료를 받을 수 있도록 돕고 있습니다.

기술의 발전은 자궁체부암 치료에 어떤 혁명을 가져오고 있는가?

기술 혁신은 자궁체부암의 진단과 치료를 발전시키는 데 있어 매우 중요합니다. 로봇 보조 수술과 같은 최소침습 수술 기법의 등장으로 회복 시간이 단축되고 수술 결과가 개선되어 환자들에게 합병증이 적은 최소침습적 치료 옵션을 제공합니다. 또한, 표적치료제와 면역치료제의 개발은 특히 진행성 및 재발성 자궁체부암 환자의 치료에 새로운 길을 열어주었습니다. 이러한 치료법은 암의 증식에 관여하는 특정 분자를 표적으로 삼아 기존 화학요법에 비해 부작용이 적고, 보다 정밀하고 효과적인 치료를 가능하게 합니다. 진단 측면에서는 차세대 염기서열 분석(NGS)과 액체 생검이 유전자 돌연변이를 식별하고 치료 반응을 실시간으로 모니터링하는 강력한 도구로 부상하고 있습니다. 이러한 발전은 임상의가 더 많은 정보에 입각한 결정을 내리고, 필요에 따라 치료를 조정하고, 보다 맞춤화된 치료를 제공할 수 있도록 돕습니다.

자궁경부암의 첨단 진단 및 치료법 채택을 촉진하는 요인은 무엇인가?

자궁내막암의 유병률 증가, 특히 고령화 및 생활습관 관련 위험 요인을 가진 집단에서 자궁내막암의 유병률이 증가함에 따라 첨단 진단 및 치료법의 채택이 촉진되고 있습니다. 자궁체부암의 증상과 조기 발견의 중요성에 대한 인식이 높아짐에 따라 더 많은 여성들이 정기적인 검진을 받고 있으며, 이는 조기 진단과 치료 결과를 개선하는 데 기여하고 있습니다. 또한, 의료 서비스 제공업체들은 유전자 검사 및 분자생물학적 검사를 활용하여 치료 방침을 결정하는 데 도움을 주는 개인 맞춤형 의료 접근법을 채택하고 있습니다. 이러한 정밀의료로의 전환은 자궁체부암에서 특정 유전자 변이와 치료 효과의 연관성을 입증하는 연구 결과가 증가하면서 뒷받침되고 있습니다. 또한, 선진국과 신흥국 시장에서의 의료비 지출 증가는 고급 진단과 치료에 대한 접근성을 높여 생존율과 환자 예후를 개선하는 데 기여하고 있습니다. 종양 전문의, 방사선 전문의, 병리학자, 유전상담사 등 다학제 진료팀의 역할이 확대되면서 자궁체부암 환자를 위한 종합적이고 협력적인 치료 제공이 강화되고 있습니다.

자궁암 치료 및 진단 시장의 성장을 가속하는 요인은 무엇인가?

자궁암 치료 및 진단 시장의 성장은 진단 기술의 발전, 개인 맞춤형 치료 옵션 증가, 전 세계 자궁체부암 유병률 증가 등 여러 요인에 의해 주도되고 있습니다. 분자진단 및 바이오마커 기반 치료의 발전은 보다 표적화되고 효과적인 치료 전략을 가능하게 하는 기술 혁신으로 시장 확대에 크게 기여하고 있습니다. 또한, 정기적인 검진 및 첨단 영상진단 기술을 통한 조기 발견에 대한 중요성이 강조되면서 진단 서비스에 대한 수요가 증가하고 있습니다. 자궁체부암에 대한 인식이 높아지고 적시에 개입하는 것이 중요하다는 인식이 높아지면서 첨단 치료와 진단에 대한 환자들 수요도 증가하고 있습니다. 또한, 선진국과 신흥국 시장 모두에서 의료비 지출이 증가함에 따라 이러한 첨단 기술에 대한 광범위한 접근이 가능해져 시장 성장을 더욱 촉진하고 있습니다. 마지막으로, 표적치료제 및 면역요법을 포함한 새로운 치료제의 파이프라인이 확대되고 있으며, 이러한 치료법은 진행성 및 저항성 자궁체부암 환자에게 새로운 희망을 가져다 줄 수 있기 때문에 향후에도 시장을 주도할 것으로 예상됩니다.

조사 대상 기업 예(주목 46사)

  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 24.09.10

Global Uterine Cancer Therapeutics and Diagnostics Market to Reach US$28.2 Billion by 2030

The global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$21.4 Billion in the year 2023, is expected to reach US$28.2 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2023-2030. Endometrial Carcinomas Therapeutics and Diagnostics, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$19.0 Billion by the end of the analysis period. Growth in the Uterine Sarcomas Therapeutics and Diagnostics segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.7 Billion While China is Forecast to Grow at 7.5% CAGR

The Uterine Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$5.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Uterine Cancer Therapeutics and Diagnostics Market - Key Trends & Drivers Summarized

Why Is Uterine Cancer Detection and Treatment So Vital?

Uterine cancer, one of the most common cancers affecting women, primarily includes endometrial cancer and uterine sarcomas. Early detection and effective treatment are critical for improving survival rates and quality of life. As the incidence of uterine cancer rises globally, the demand for advanced therapeutics and diagnostics has intensified. Early-stage detection through techniques like transvaginal ultrasound, endometrial biopsy, and advanced imaging methods can significantly improve treatment outcomes. Moreover, personalized treatment approaches, including surgery, radiation therapy, chemotherapy, and hormone therapy, have evolved to target specific cancer types and stages, improving patient outcomes and minimizing side effects. The integration of molecular diagnostics and biomarker testing has further refined the ability to tailor treatments, ensuring that patients receive the most effective therapies based on the genetic makeup of their tumors.

How Are Technological Advancements Revolutionizing Uterine Cancer Care?

Technological innovations have been pivotal in advancing both the diagnosis and treatment of uterine cancer. The advent of minimally invasive surgical techniques, such as robotic-assisted surgery, has reduced recovery times and improved surgical outcomes, offering patients less invasive options with fewer complications. Additionally, the development of targeted therapies and immunotherapies has opened new avenues for treatment, particularly for patients with advanced or recurrent uterine cancer. These therapies work by targeting specific molecules involved in cancer growth, allowing for more precise and effective treatment with fewer side effects compared to traditional chemotherapy. On the diagnostics front, next-generation sequencing (NGS) and liquid biopsies are emerging as powerful tools for identifying genetic mutations and monitoring treatment responses in real-time. These advancements enable clinicians to make more informed decisions, adjust treatments as needed, and provide more personalized care.

What Is Driving the Adoption of Advanced Diagnostics and Therapeutics in Uterine Cancer?

The increasing prevalence of uterine cancer, particularly in aging populations and those with lifestyle-related risk factors, is driving the adoption of advanced diagnostics and therapeutics. As awareness of uterine cancer symptoms and the importance of early detection grows, more women are undergoing regular screenings, leading to earlier diagnosis and better treatment outcomes. Additionally, healthcare providers are increasingly adopting personalized medicine approaches, utilizing genetic and molecular testing to guide treatment decisions. This shift towards precision medicine is supported by the growing body of research linking specific genetic mutations to treatment responses in uterine cancer. Furthermore, the rising healthcare expenditures in developed and emerging markets are enabling greater access to advanced diagnostics and treatments, contributing to improved survival rates and patient outcomes. The expanding role of multidisciplinary care teams, including oncologists, radiologists, pathologists, and genetic counselors, is also enhancing the delivery of comprehensive and coordinated care for uterine cancer patients.

What Factors Are Driving the Growth in the Uterine Cancer Therapeutics and Diagnostics Market?

The growth in the Uterine Cancer Therapeutics and Diagnostics market is driven by several factors, including advancements in diagnostic technologies, the increasing availability of personalized treatment options, and the rising prevalence of uterine cancer worldwide. The ongoing development of molecular diagnostics and biomarker-driven therapies is significantly contributing to market expansion, as these innovations allow for more targeted and effective treatment strategies. Additionally, the growing emphasis on early detection through regular screenings and the use of advanced imaging techniques is increasing the demand for diagnostic services. The rising awareness of uterine cancer and the importance of timely intervention are also driving patient demand for cutting-edge therapies and diagnostics. Furthermore, the increasing healthcare expenditure in both developed and emerging markets is enabling broader access to these advanced technologies, further fueling market growth. Finally, the expanding pipeline of new therapeutics, including targeted therapies and immunotherapies, is expected to continue driving the market as these treatments offer new hope for patients with advanced or resistant forms of uterine cancer.

Select Competitors (Total 46 Featured) -

  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Uterine Cancer Therapeutics and Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Uterine Cancer Driving Demand forg Advanced Therapeutics
    • Rising Adoption of Personalized Medicine in Cancer Treatment
    • Advancements in Genomic Testing Enhancing Early Diagnosis Capabilities
    • Growing Demand for Minimally Invasive Surgical Techniques
    • Development of Targeted Therapies Creating New Market Opportunities
    • Impact of Aging Population on Uterine Cancer Incidence
    • Increasing Investments in Cancer Research and Development
    • Adoption of AI and Machine Learning in Diagnostic Technologies
    • Rising Awareness and Screening Programs Boosting Early Detection Rates
    • Growing Demand for Combination Therapies in Cancer Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Uterine Sarcomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Endometrial Carcinomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Uterine Cancer Therapeutics and Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • JAPAN
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • CHINA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • EUROPE
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • FRANCE
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: France 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • GERMANY
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • INDIA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: India 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • AFRICA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제